Pegcrisantaspase

DRUG3 trials

Sponsors

Jazz Pharmaceuticals, M.D. Anderson Cancer Center, National Cancer Institute (NCI)

Conditions

Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDown SyndromeLymphoblastic LymphomaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent B Acute Lymphoblastic Leukemia

Phase 1

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

TerminatedNCT04526795

M.D. Anderson Cancer CenterBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia +8

Start: 2021-04-09End: 2024-11-15Updated: 2024-12-12

Phase 2

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

TerminatedNCT02257684

Jazz PharmaceuticalsAcute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Start: 2014-09-30End: 2016-01-31Updated: 2017-04-04

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingNCT04546399

National Cancer Institute (NCI)Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia

Start: 2020-12-17End: 2028-06-30Target: 461Updated: 2025-09-10

Related Papers

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.

2022-12-0112 citations